Financhill
Sell
46

SWTX Quote, Financials, Valuation and Earnings

Last price:
$49.86
Seasonality move :
-8.46%
Day range:
$47.70 - $51.01
52-week range:
$28.21 - $62.00
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
19.79x
P/B ratio:
7.97x
Volume:
1.7M
Avg. volume:
3.2M
1-year change:
3.35%
Market cap:
$3.8B
Revenue:
$191.6M
EPS (TTM):
-$3.48

Price Performance History

Performance vs. Valuation Benchmarks

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Competitors

Company Revenue Forecast Earnings Forecast Revenue Growth Forecast Earnings Growth Forecast Analyst Price Target Median
SWTX
SpringWorks Therapeutics
$60.5M -$0.71 218.64% -37.01% $72.88
ACAD
ACADIA Pharmaceuticals
$272.1M $0.22 16.28% -91.94% $24.85
ADMA
ADMA Biologics
$112.8M $0.15 41.07% 75% $25.27
ATRA
Atara Biotherapeutics
$16.6M -$3.49 -87.43% -61.97% $12.25
GRCE
Grace Therapeutics
-- -$0.32 -- -63.24% $11.88
INSM
Insmed
$102.4M -$1.16 19.4% -27.03% $95.66
Company Price Analyst Target Market Cap P/E Ratio Dividend per Share Dividend Yield Price / LTM Sales
SWTX
SpringWorks Therapeutics
$51.14 $72.88 $3.8B -- $0.00 0% 19.79x
ACAD
ACADIA Pharmaceuticals
$17.20 $24.85 $2.9B 12.65x $0.00 0% 2.99x
ADMA
ADMA Biologics
$18.67 $25.27 $4.4B 22.77x $0.00 0% 10.61x
ATRA
Atara Biotherapeutics
$7.17 $12.25 $42M -- $0.00 0% 0.42x
GRCE
Grace Therapeutics
$2.18 $11.88 $29.9M -- $0.00 0% --
INSM
Insmed
$76.53 $95.66 $13.9B -- $0.00 0% 34.51x
Company Total Debt / Total Capital Beta Debt to Equity Quick Ratio
SWTX
SpringWorks Therapeutics
-- 0.555 -- 3.54x
ACAD
ACADIA Pharmaceuticals
-- -0.163 -- 2.18x
ADMA
ADMA Biologics
17.17% 4.789 1.78% 2.76x
ATRA
Atara Biotherapeutics
-- -0.649 -- 0.33x
GRCE
Grace Therapeutics
-- 0.948 -- --
INSM
Insmed
79.45% 6.110 8.91% 4.99x
Company Gross Profit Operating Income Return on Invested Capital Return on Common Equity EBIT Margin Free Cash Flow
SWTX
SpringWorks Therapeutics
$56M -$81.3M -46.69% -46.69% -132.16% -$35.6M
ACAD
ACADIA Pharmaceuticals
$237.8M $7M 41.59% 41.59% 2.69% $39.9M
ADMA
ADMA Biologics
$63.3M $38.3M 60.85% 93.41% 31.98% $23.9M
ATRA
Atara Biotherapeutics
$26M -$12.2M -2818.48% -2818.48% -35.71% -$24.6M
GRCE
Grace Therapeutics
-- -$3.7M -- -- -- -$4.1M
INSM
Insmed
$78.3M -$245.2M -82.19% -41989.34% -205.36% -$202.8M

SpringWorks Therapeutics vs. Competitors

  • Which has Higher Returns SWTX or ACAD?

    ACADIA Pharmaceuticals has a net margin of -125.59% compared to SpringWorks Therapeutics's net margin of 55.37%. SpringWorks Therapeutics's return on equity of -46.69% beat ACADIA Pharmaceuticals's return on equity of 41.59%.

    Company Gross Margin Earnings Per Share Invested Capital
    SWTX
    SpringWorks Therapeutics
    90.98% -$1.04 $481.1M
    ACAD
    ACADIA Pharmaceuticals
    91.6% $0.86 $732.8M
  • What do Analysts Say About SWTX or ACAD?

    SpringWorks Therapeutics has a consensus price target of $72.88, signalling upside risk potential of 42.5%. On the other hand ACADIA Pharmaceuticals has an analysts' consensus of $24.85 which suggests that it could grow by 44.48%. Given that ACADIA Pharmaceuticals has higher upside potential than SpringWorks Therapeutics, analysts believe ACADIA Pharmaceuticals is more attractive than SpringWorks Therapeutics.

    Company Buy Ratings Hold Ratings Sell Ratings
    SWTX
    SpringWorks Therapeutics
    5 0 0
    ACAD
    ACADIA Pharmaceuticals
    6 7 0
  • Is SWTX or ACAD More Risky?

    SpringWorks Therapeutics has a beta of 0.757, which suggesting that the stock is 24.323% less volatile than S&P 500. In comparison ACADIA Pharmaceuticals has a beta of 0.426, suggesting its less volatile than the S&P 500 by 57.361%.

  • Which is a Better Dividend Stock SWTX or ACAD?

    SpringWorks Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. ACADIA Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. SpringWorks Therapeutics pays -- of its earnings as a dividend. ACADIA Pharmaceuticals pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios SWTX or ACAD?

    SpringWorks Therapeutics quarterly revenues are $61.5M, which are smaller than ACADIA Pharmaceuticals quarterly revenues of $259.6M. SpringWorks Therapeutics's net income of -$77.3M is lower than ACADIA Pharmaceuticals's net income of $143.7M. Notably, SpringWorks Therapeutics's price-to-earnings ratio is -- while ACADIA Pharmaceuticals's PE ratio is 12.65x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for SpringWorks Therapeutics is 19.79x versus 2.99x for ACADIA Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    SWTX
    SpringWorks Therapeutics
    19.79x -- $61.5M -$77.3M
    ACAD
    ACADIA Pharmaceuticals
    2.99x 12.65x $259.6M $143.7M
  • Which has Higher Returns SWTX or ADMA?

    ADMA Biologics has a net margin of -125.59% compared to SpringWorks Therapeutics's net margin of 95.19%. SpringWorks Therapeutics's return on equity of -46.69% beat ADMA Biologics's return on equity of 93.41%.

    Company Gross Margin Earnings Per Share Invested Capital
    SWTX
    SpringWorks Therapeutics
    90.98% -$1.04 $481.1M
    ADMA
    ADMA Biologics
    53.88% $0.46 $421.4M
  • What do Analysts Say About SWTX or ADMA?

    SpringWorks Therapeutics has a consensus price target of $72.88, signalling upside risk potential of 42.5%. On the other hand ADMA Biologics has an analysts' consensus of $25.27 which suggests that it could grow by 35.36%. Given that SpringWorks Therapeutics has higher upside potential than ADMA Biologics, analysts believe SpringWorks Therapeutics is more attractive than ADMA Biologics.

    Company Buy Ratings Hold Ratings Sell Ratings
    SWTX
    SpringWorks Therapeutics
    5 0 0
    ADMA
    ADMA Biologics
    4 0 0
  • Is SWTX or ADMA More Risky?

    SpringWorks Therapeutics has a beta of 0.757, which suggesting that the stock is 24.323% less volatile than S&P 500. In comparison ADMA Biologics has a beta of 0.605, suggesting its less volatile than the S&P 500 by 39.509%.

  • Which is a Better Dividend Stock SWTX or ADMA?

    SpringWorks Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. ADMA Biologics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. SpringWorks Therapeutics pays -- of its earnings as a dividend. ADMA Biologics pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios SWTX or ADMA?

    SpringWorks Therapeutics quarterly revenues are $61.5M, which are smaller than ADMA Biologics quarterly revenues of $117.5M. SpringWorks Therapeutics's net income of -$77.3M is lower than ADMA Biologics's net income of $111.9M. Notably, SpringWorks Therapeutics's price-to-earnings ratio is -- while ADMA Biologics's PE ratio is 22.77x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for SpringWorks Therapeutics is 19.79x versus 10.61x for ADMA Biologics. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    SWTX
    SpringWorks Therapeutics
    19.79x -- $61.5M -$77.3M
    ADMA
    ADMA Biologics
    10.61x 22.77x $117.5M $111.9M
  • Which has Higher Returns SWTX or ATRA?

    Atara Biotherapeutics has a net margin of -125.59% compared to SpringWorks Therapeutics's net margin of -38.75%. SpringWorks Therapeutics's return on equity of -46.69% beat Atara Biotherapeutics's return on equity of -2818.48%.

    Company Gross Margin Earnings Per Share Invested Capital
    SWTX
    SpringWorks Therapeutics
    90.98% -$1.04 $481.1M
    ATRA
    Atara Biotherapeutics
    79.25% -$1.19 -$97.3M
  • What do Analysts Say About SWTX or ATRA?

    SpringWorks Therapeutics has a consensus price target of $72.88, signalling upside risk potential of 42.5%. On the other hand Atara Biotherapeutics has an analysts' consensus of $12.25 which suggests that it could grow by 70.85%. Given that Atara Biotherapeutics has higher upside potential than SpringWorks Therapeutics, analysts believe Atara Biotherapeutics is more attractive than SpringWorks Therapeutics.

    Company Buy Ratings Hold Ratings Sell Ratings
    SWTX
    SpringWorks Therapeutics
    5 0 0
    ATRA
    Atara Biotherapeutics
    4 2 0
  • Is SWTX or ATRA More Risky?

    SpringWorks Therapeutics has a beta of 0.757, which suggesting that the stock is 24.323% less volatile than S&P 500. In comparison Atara Biotherapeutics has a beta of 0.487, suggesting its less volatile than the S&P 500 by 51.322%.

  • Which is a Better Dividend Stock SWTX or ATRA?

    SpringWorks Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Atara Biotherapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. SpringWorks Therapeutics pays -- of its earnings as a dividend. Atara Biotherapeutics pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios SWTX or ATRA?

    SpringWorks Therapeutics quarterly revenues are $61.5M, which are larger than Atara Biotherapeutics quarterly revenues of $32.8M. SpringWorks Therapeutics's net income of -$77.3M is lower than Atara Biotherapeutics's net income of -$12.7M. Notably, SpringWorks Therapeutics's price-to-earnings ratio is -- while Atara Biotherapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for SpringWorks Therapeutics is 19.79x versus 0.42x for Atara Biotherapeutics. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    SWTX
    SpringWorks Therapeutics
    19.79x -- $61.5M -$77.3M
    ATRA
    Atara Biotherapeutics
    0.42x -- $32.8M -$12.7M
  • Which has Higher Returns SWTX or GRCE?

    Grace Therapeutics has a net margin of -125.59% compared to SpringWorks Therapeutics's net margin of --. SpringWorks Therapeutics's return on equity of -46.69% beat Grace Therapeutics's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    SWTX
    SpringWorks Therapeutics
    90.98% -$1.04 $481.1M
    GRCE
    Grace Therapeutics
    -- -$0.36 --
  • What do Analysts Say About SWTX or GRCE?

    SpringWorks Therapeutics has a consensus price target of $72.88, signalling upside risk potential of 42.5%. On the other hand Grace Therapeutics has an analysts' consensus of $11.88 which suggests that it could grow by 444.87%. Given that Grace Therapeutics has higher upside potential than SpringWorks Therapeutics, analysts believe Grace Therapeutics is more attractive than SpringWorks Therapeutics.

    Company Buy Ratings Hold Ratings Sell Ratings
    SWTX
    SpringWorks Therapeutics
    5 0 0
    GRCE
    Grace Therapeutics
    1 0 0
  • Is SWTX or GRCE More Risky?

    SpringWorks Therapeutics has a beta of 0.757, which suggesting that the stock is 24.323% less volatile than S&P 500. In comparison Grace Therapeutics has a beta of 1.193, suggesting its more volatile than the S&P 500 by 19.308%.

  • Which is a Better Dividend Stock SWTX or GRCE?

    SpringWorks Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Grace Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. SpringWorks Therapeutics pays -- of its earnings as a dividend. Grace Therapeutics pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios SWTX or GRCE?

    SpringWorks Therapeutics quarterly revenues are $61.5M, which are larger than Grace Therapeutics quarterly revenues of --. SpringWorks Therapeutics's net income of -$77.3M is lower than Grace Therapeutics's net income of -$4.2M. Notably, SpringWorks Therapeutics's price-to-earnings ratio is -- while Grace Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for SpringWorks Therapeutics is 19.79x versus -- for Grace Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    SWTX
    SpringWorks Therapeutics
    19.79x -- $61.5M -$77.3M
    GRCE
    Grace Therapeutics
    -- -- -- -$4.2M
  • Which has Higher Returns SWTX or INSM?

    Insmed has a net margin of -125.59% compared to SpringWorks Therapeutics's net margin of -225.53%. SpringWorks Therapeutics's return on equity of -46.69% beat Insmed's return on equity of -41989.34%.

    Company Gross Margin Earnings Per Share Invested Capital
    SWTX
    SpringWorks Therapeutics
    90.98% -$1.04 $481.1M
    INSM
    Insmed
    74.96% -$1.32 $1.4B
  • What do Analysts Say About SWTX or INSM?

    SpringWorks Therapeutics has a consensus price target of $72.88, signalling upside risk potential of 42.5%. On the other hand Insmed has an analysts' consensus of $95.66 which suggests that it could grow by 25%. Given that SpringWorks Therapeutics has higher upside potential than Insmed, analysts believe SpringWorks Therapeutics is more attractive than Insmed.

    Company Buy Ratings Hold Ratings Sell Ratings
    SWTX
    SpringWorks Therapeutics
    5 0 0
    INSM
    Insmed
    12 0 0
  • Is SWTX or INSM More Risky?

    SpringWorks Therapeutics has a beta of 0.757, which suggesting that the stock is 24.323% less volatile than S&P 500. In comparison Insmed has a beta of 1.280, suggesting its more volatile than the S&P 500 by 27.99%.

  • Which is a Better Dividend Stock SWTX or INSM?

    SpringWorks Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Insmed offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. SpringWorks Therapeutics pays -- of its earnings as a dividend. Insmed pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios SWTX or INSM?

    SpringWorks Therapeutics quarterly revenues are $61.5M, which are smaller than Insmed quarterly revenues of $104.4M. SpringWorks Therapeutics's net income of -$77.3M is higher than Insmed's net income of -$235.5M. Notably, SpringWorks Therapeutics's price-to-earnings ratio is -- while Insmed's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for SpringWorks Therapeutics is 19.79x versus 34.51x for Insmed. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    SWTX
    SpringWorks Therapeutics
    19.79x -- $61.5M -$77.3M
    INSM
    Insmed
    34.51x -- $104.4M -$235.5M

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Is the Market Going to Go Lower?
Is the Market Going to Go Lower?

The last month has been extremely difficult for the stock…

2 Dividend Stocks to Buy in a Recession
2 Dividend Stocks to Buy in a Recession

While many economists and investors initially expected 2025 to be…

Is Ford Stock Undervalued Amid the EV Transition?
Is Ford Stock Undervalued Amid the EV Transition?

There is a lot going on in the electric vehicle…

Stock Ideas

Buy
53
Is AAPL Stock a Buy?

Market Cap: $3.2T
P/E Ratio: 35x

Buy
56
Is NVDA Stock a Buy?

Market Cap: $3T
P/E Ratio: 41x

Buy
51
Is MSFT Stock a Buy?

Market Cap: $2.9T
P/E Ratio: 33x

Alerts

Sell
49
SMTC alert for Mar 17

Semtech [SMTC] is down 0.49% over the past day.

Buy
62
PLPC alert for Mar 17

Preformed Line Products [PLPC] is up 3.8% over the past day.

Sell
50
NUTX alert for Mar 17

Nutex Health [NUTX] is up 4.82% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock